Bulletin
Investor Alert

Apellis Pharmaceuticals Inc.

NAS: APLS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 19, 2022, 4:36 p.m.

/zigman2/quotes/202103251/composite

$

44.48

Change

0.00 0.00%

Volume

Volume 31,727

Quotes are delayed by 20 min

/zigman2/quotes/202103251/composite

Today's close

$ 43.52

$ 44.48

Change

+0.96 +2.21%

Day low

Day high

$41.81

$45.15

Open

52 week low

52 week high

$27.50

$73.00

Open

Company Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Desc...

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Valuation

Price to Sales Ratio

59.96

Price to Book Ratio

23.21

Enterprise Value to EBITDA

-7.48

Enterprise Value to Sales

49.41

Efficiency

Total Asset Turnover

0.07

Liquidity

Current Ratio

6.25

Quick Ratio

6.13

Cash Ratio

5.33

Profitability

Gross Margin

97.46

Operating Margin

-805.67

Pretax Margin

-1,120.75

Net Margin

-1,121.27

Return on Assets

-81.02

Return on Equity

-370.20

Return on Total Capital

-108.21

Capital Structure

Total Debt to Total Assets

23.84

Officers and Executives

Name Age Officer Since Title
Dr. Cedric Francois 48 2009 President, Chief Executive Officer & Director
Mr. Timothy Eugene Sullivan 49 2017 Chief Financial Officer & Treasurer
Ms. Nur Nicholson - 2020 Chief Technical Operations Officer
Dr. Pascal Deschatelets 49 2009 Secretary & Director
Dr. Federico Grossi 46 2010 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/02/2022 Federico Grossi
CHIEF MEDICAL OFFICER
2,500   Disposition at $43.56 per share. 108,900
04/29/2022 Pascal Deschatelets
Chief Scientific Officer
4,000   Disposition at $44.43 per share. 177,720
04/29/2022 Pascal Deschatelets
Chief Scientific Officer
4,000   Derivative/Non-derivative trans. at $2.67 per share. 10,680
04/25/2022 David O. Watson
General Counsel
5,000   Disposition at $50 per share. 250,000
04/22/2022 Andrew Sinclair Dunlop
Director
20,000   Derivative/Non-derivative trans. at $14 per share. 280,000
04/21/2022 Pascal Deschatelets
Chief Scientific Officer
1,875   0
04/21/2022 David O. Watson
General Counsel
1,875   0
04/21/2022 Federico Grossi
CHIEF MEDICAL OFFICER
1,875   0
04/20/2022 Mark DeLong
Senior Vice President
7,000   Disposition at $52.53 per share. 367,710
04/20/2022 Mark DeLong
Senior Vice President
7,000   Derivative/Non-derivative trans. at $15.52 per share. 108,640
04/14/2022 Alec Machiels
Director
1,250   Disposition at $50.9 per share. 63,625
04/14/2022 Alec Machiels
Director
1,250   Derivative/Non-derivative trans. at $2.67 per share. 3,337
04/05/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
609   Disposition at $60.09 per share. 36,594
04/05/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
609   Derivative/Non-derivative trans. at $13.85 per share. 8,434
04/04/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
1,249   Disposition at $57.8 per share. 72,192
04/04/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
1,437   Disposition at $56.86 per share. 81,707
04/04/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
818   Disposition at $55.84 per share. 45,677
04/04/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
3,504   Derivative/Non-derivative trans. at $13.85 per share. 48,530
04/01/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
11,496   Disposition at $55.05 per share. 632,854
04/01/2022 Lukas Scheibler
CHIEF INNOVATION OFFICER
11,496   Derivative/Non-derivative trans. at $13.85 per share. 159,219
/news/latest/company/us/apls

MarketWatch News on APLS

  1. 4 Midsize Biotech Stocks That Have Breakout Potential

    10:02 a.m. Sept. 23, 2021

    - Barron's Online

  2. Apellis Stock Plunges After Its Eye Treatment Gets Mixed Results

    1:02 p.m. Sept. 10, 2021

    - Barron's Online

  3. Apellis Pharmaceuticals downgraded to neutral from outperform at Wedbush

    7:20 a.m. Sept. 10, 2021

    - Tomi Kilgore

  4. Apellis stock price target cut to $57 from $101 at J.P. Morgan

    6:58 a.m. Sept. 10, 2021

    - Tomi Kilgore

  5. Apellis Pharmaceuticals upgraded to outperform from neutral at Wedbush

    7:18 a.m. Aug. 19, 2021

    - Tomi Kilgore

  6. video content What Happens to a Biotech Stock After a Vaccine is Developed?

    10:27 a.m. June 25, 2021

    - Barrons.com

  7. Apellis Pharmaceuticals price target raised to $104 from $78, stock rated strong buy

    8:49 a.m. Jan. 8, 2021

    - Tonya Garcia

  8. Apellis stock price target raised to $87 from $50 at J.P. Morgan

    8:03 a.m. Dec. 4, 2020

    - Tomi Kilgore

  9. Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus

    7:34 a.m. Sept. 1, 2020

    - Tomi Kilgore

  10. 21 Risky Stocks That Might Have Borrowed Too Much

    11:47 a.m. May 19, 2020

    - Barron's Online

  11. Apellis Pharmaceuticals started at strong buy with $86 stock price target at Raymond James

    7:41 a.m. April 1, 2020

    - Tomi Kilgore

  12. Apellis Pharmaceuticals upgraded to neutral from underperform at Wedbush

    7:47 a.m. March 11, 2020

    - Tomi Kilgore

  13. Apellis Pharmaceuticals stock price target raised to $62 from $52 at Oppenheimer

    8:14 a.m. Jan. 8, 2020

    - Tomi Kilgore

  14. Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion

    11:30 a.m. Jan. 7, 2020

    - Barron's Online

  15. Apellis Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan

    6:56 a.m. July 12, 2019

    - Tomi Kilgore

  16. Loading more headlines...
/news/nonmarketwatch/company/us/apls

Other News on APLS

  1. 10-Q: APELLIS PHARMACEUTICALS, INC.

    4:08 p.m. May 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates

    9:34 a.m. March 1, 2022

    - Zacks.com

  3. 10-K: APELLIS PHARMACEUTICALS, INC.

    5:08 p.m. Feb. 28, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Apellis Pharmaceuticals Q4 2021 Earnings Preview

    5:35 p.m. Feb. 25, 2022

    - Seeking Alpha

  5. Loading more headlines...

At a Glance

Apellis Pharmaceuticals, Inc.

100 5th Avenue

Waltham, Massachusetts 02451-8703

Phone

1 6179775700

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$66.56M

Net Income

$-746.35M

Employees

476.00

/news/pressrelease/company/us/apls

Press Releases on APLS

  1. Loading more headlines...
Link to MarketWatch's Slice.